| Date Filed | Type | Description |
| 10/04/2023 |
4
| Dummer Wolfgang (Chief Medical Officer) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 200,000 options to buy
@ $11.37, valued at
$2.3M
|
|
| 10/04/2023 |
3
| Dummer Wolfgang (Chief Medical Officer) has filed a Form 3 on ALPINE IMMUNE SCIENCES, INC. |
| 08/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/14/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP has filed a Schedule 13D for ALPINE IMMUNE SCIENCES, INC. |
| 02/14/2023 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 7.9% stake in ALPINE IMMUNE SCIENCES, INC. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.6% stake in ALPINE IMMUNE SCIENCES, INC. |
| 02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 6.8% stake in Alpine Immune Sciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4% stake in Alpine Immune Sciences, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/26/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 01/05/2023 |
4
| Sandler Andrew Seth (Chief Medical Officer) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 50,000 options to buy
@ $0 |
|
| 01/05/2023 |
4
| Thompson Peter A. (Director) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 10,000 options to buy
@ $0 |
|
| 01/05/2023 |
4
| GOLD MITCHELL (Executive Chairman and CEO) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 350,000 options to buy
@ $0 |
|
| 01/05/2023 |
4
| Rickey James Paul (See Remarks) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 109,000 options to buy
@ $0 |
|
| 01/05/2023 |
4
| PENG STANFORD L (See Remarks) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 150,000 options to buy
@ $0 |
|
| 01/05/2023 |
4
| Topper James N (Director) has filed a Form 4 on ALPINE IMMUNE SCIENCES, INC.|
Txns:
| Granted 10,000 options to buy
@ $0 |
|
|